FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes

AIMS/HYPOTHESIS: Fibroblast growth factor 21 (FGF21) is considered to be a promising therapeutic candidate for the treatment of type 2 diabetes. However, as FGF21 levels are elevated in obese and diabetic conditions we aimed to test if exogenous FGF21 is sufficient to prevent diabetes and beta cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Laeger, Thomas, Baumeier, Christian, Wilhelmi, Ilka, Würfel, Josefine, Kamitz, Anne, Schürmann, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448882/
https://www.ncbi.nlm.nih.gov/pubmed/28770320
http://dx.doi.org/10.1007/s00125-017-4389-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448882/
https://www.ncbi.nlm.nih.gov/pubmed/28770320
http://dx.doi.org/10.1007/s00125-017-4389-x

Ejemplares similares